Literature DB >> 8878461

The cytocidal activity of OK-432-activated mononuclear cells against human glioma cells is partly mediated through the Fas ligand/Fas system.

K Toda1, T Shiraishi, T Hirotsu, K Fukuyama, T Mineta, S Kawaguchi, K Tabuchi.   

Abstract

We have been applying an adoptive immunotherapy protocol to patients with malignant brain tumors using OK-432-activated peripheral blood mononuclear cells (OK-MCs). In order to elucidate the mechanism of OK-MCs' cytotoxicity, we examined the expression of Fas ligand mRNA in OK-MCs and the cytocidal activity of these cells against a human glioma cell line, T98G which expresses a high level of Fas. The expression of Fas ligand mRNA was low in non-treated peripheral blood mononuclear cells and was elevated by treatment with OK-432, irrespective of the dose employed. Apoptosis of T98G cells induced by OK-MCs was unequivocally inhibited by the pretreatment of T98 G cells with ZB4 monoclonal antibody, which binds to Fas and blocks the binding of Fas ligand to Fas. These data indicate that the cytotoxic activity of OK-MCs via apoptosis seems to be at least partly mediated by the Fas ligand/Fas system. Adoptive immunotherapy using the Fas ligand/Fas system could be a new treatment modality for human malignant brain tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878461      PMCID: PMC5921210          DOI: 10.1111/j.1349-7006.1996.tb02128.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  23 in total

1.  A possible clinical application of multicytokine-producing cytotoxic mononuclear cell (MCCM) therapy.

Authors:  M Katano; E Kubota; H Yamamoto; M Nakamura; T Matsuo; T Hisatsugu; T Katsuki; H Koga; K Ikezaki; K Tabuchi
Journal:  Biotherapy       Date:  1991

2.  Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: a regulatory pathway?

Authors:  F Vignaux; P Golstein
Journal:  Eur J Immunol       Date:  1994-04       Impact factor: 5.532

Review 3.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

4.  Streptococcal preparation OK-432-induced interferon in human leukocytes: purification and characterization.

Authors:  M De Ley; H Claeys
Journal:  Int Arch Allergy Appl Immunol       Date:  1984

5.  Detection of DNA strand breaks associated with apoptosis in human brain tumors.

Authors:  S Nakagawa; T Shiraishi; S Kihara; K Tabuchi
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  The antitumor effects of locally injecting human peripheral blood mononuclear cells treated with OK-432 into the tumor site: the possible role of a tumor growth inhibitory factor (TGIF).

Authors:  M Katano; T Mizoguchi; H Yamamoto; M Nakamura; T Matsuo; T Hisatugu; T Kisu; K Yamaoka; O Tokunaga
Journal:  Jpn J Surg       Date:  1990-01

7.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.

Authors:  T Takahashi; M Tanaka; C I Brannan; N A Jenkins; N G Copeland; T Suda; S Nagata
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

8.  Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

Authors:  D Barba; S C Saris; C Holder; S A Rosenberg; E H Oldfield
Journal:  J Neurosurg       Date:  1989-02       Impact factor: 5.115

Review 9.  Fas and Fas ligand: lpr and gld mutations.

Authors:  S Nagata; T Suda
Journal:  Immunol Today       Date:  1995-01

10.  Effective induction of human NK cells with OK-432 and further augmentation of their cytolytic function by rIL-2.

Authors:  Z L Hu; E Kubota; H Imamura; M Katano; T Katsuki
Journal:  Microbiol Immunol       Date:  1994       Impact factor: 1.955

View more
  5 in total

1.  Human astrocytomas co-expressing Fas and Fas ligand also produce TGFbeta2 and Bcl-2.

Authors:  B Frankel; S L Longo; T C Ryken
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

2.  Apoptosis and survival in high-grade astrocytomas as related to tumor Fas (APO-1/CD95) expression.

Authors:  Bruce Frankel; Sharon L Longo; Christopher Leach; Gregory W Canute; Timothy C Ryken
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

3.  The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients.

Authors:  A Gochi; K Orita; S Fuchimoto; N Tanaka; N Ogawa
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

4.  Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity.

Authors:  Terutsugu Koya; Ryu Yanagisawa; Yumiko Higuchi; Kenji Sano; Shigetaka Shimodaira
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

5.  OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of Asthma.

Authors:  Cheng-Jang Wu; Pin-Hsun Tseng; Cheng-Chi Chan; Sara Quon; Li-Chen Chen; Ming-Ling Kuo
Journal:  J Immunol Res       Date:  2018-10-08       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.